Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (140) 140
index medicus (105) 105
male (98) 98
female (97) 97
middle aged (96) 96
hematology (85) 85
aged (78) 78
adult (77) 77
oncology (58) 58
treatment outcome (53) 53
cancer (52) 52
leukemia, myeloid, acute - drug therapy (51) 51
life sciences (39) 39
acute myeloid leukemia (37) 37
chemotherapy (37) 37
prognosis (37) 37
aged, 80 and over (36) 36
leukemia, myeloid, acute - genetics (34) 34
adolescent (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
leukemia, myeloid, acute - pathology (28) 28
abridged index medicus (27) 27
leukemia, myeloid, acute - mortality (27) 27
acute myeloid-leukemia (26) 26
young adult (25) 25
leukemia (24) 24
animals (22) 22
disease-free survival (21) 21
immunology (21) 21
retrospective studies (20) 20
survival analysis (20) 20
mutation (19) 19
mice (18) 18
recurrence (18) 18
survival (18) 18
antineoplastic combined chemotherapy protocols - adverse effects (17) 17
france (17) 17
remission induction (17) 17
therapy (17) 17
aml (16) 16
elderly-patients (15) 15
hemic and lymphatic diseases (15) 15
human necessities (15) 15
hygiene (15) 15
leukemia, myeloid, acute - diagnosis (15) 15
medical or veterinary science (15) 15
preparations for medical, dental, or toilet purposes (15) 15
risk factors (15) 15
apoptosis (14) 14
expression (14) 14
follow-up studies (14) 14
analysis (13) 13
diagnosis (13) 13
intensive chemotherapy (13) 13
kaplan-meier estimate (13) 13
specific therapeutic activity of chemical compounds ormedicinal preparations (13) 13
survival rate (13) 13
activation (12) 12
azacitidine (12) 12
chemistry (12) 12
cytarabine (12) 12
cytogenetics (12) 12
hematology, oncology and palliative medicine (12) 12
leukemia, myeloid, acute - metabolism (12) 12
metallurgy (12) 12
prospective studies (12) 12
stem-cell transplantation (12) 12
trial (12) 12
acute myelogenous leukemia (11) 11
adhesive processes not provided for elsewhere (11) 11
adhesives (11) 11
antineoplastic combined chemotherapy protocols - administration & dosage (11) 11
article (11) 11
basic electric elements (11) 11
care and treatment (11) 11
compositions based thereon (11) 11
cytarabine - administration & dosage (11) 11
dyes (11) 11
electric solid state devices not otherwise provided for (11) 11
electricity (11) 11
macromolecular compounds obtained by reactions only involvingcarbon-to-carbon unsaturated bonds (11) 11
miscellaneous applications of materials (11) 11
miscellaneous compositions (11) 11
natural resins (11) 11
non-mechanical aspects of adhesive processes in general (11) 11
organic macromolecular compounds (11) 11
paints (11) 11
polishes (11) 11
research (11) 11
semiconductor devices (11) 11
their preparation or chemical working-up (11) 11
time factors (11) 11
use of materials as adhesives (11) 11
antimetabolites, antineoplastic - therapeutic use (10) 10
antineoplastic agents - pharmacology (10) 10
cell line, tumor (10) 10
cohort studies (10) 10
drug administration schedule (10) 10
mutations (10) 10
older patients (10) 10
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (381) 381
French (24) 24
German (11) 11
Chinese (3) 3
Korean (2) 2
Norwegian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
by Hills, Robert K, DPhil and Castaigne, Sylvie, Prof and Appelbaum, Frederick R, Prof and Delaunay, Jacques, MD and Petersdorf, Stephen, MD and Othus, Megan, PhD and Estey, Elihu H, Prof and Dombret, Hervé, Prof and Chevret, Sylvie, PhD and Ifrah, Norbert, Prof and Cahn, Jean-Yves, Prof and Récher, Christian, Prof and Chilton, Lucy, PhD and Moorman, Anthony V, Prof and Burnett, Alan K, Prof
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 986 - 996
Summary Background Gemtuzumab ozogamicin was the first example of antibody-directed chemotherapy in cancer, and was developed for acute myeloid leukaemia.... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | YOUNGER PATIENTS | THERAPY | OLDER PATIENTS | MYLOTARG | ONCOLOGY | DISEASE | Confidence Intervals | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Cytarabine - therapeutic use | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Remission Induction - methods | Odds Ratio | Daunorubicin - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Risk Assessment | Survival Rate | Treatment Outcome | Randomized Controlled Trials as Topic | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Leukemia, Myeloid, Acute - diagnosis | Infusions, Intravenous | Aminoglycosides - therapeutic use | Chemotherapy | Adults | Analysis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text INPP4B, a new player in the chemoresistance of AML
by Recher, Christian
Blood, ISSN 0006-4971, 04/2015, Volume 125, Issue 18, pp. 2738 - 2739
HEMATOLOGY | ACUTE MYELOID-LEUKEMIA | Leukemia, Myeloid, Acute - drug therapy | Drug Resistance, Neoplasm - genetics | Leukemia, Myeloid, Acute - diagnosis | Phosphoric Monoester Hydrolases - physiology | Humans | Leukemia, Myeloid, Acute - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
by Récher, Christian, Prof and Coiffier, Bertrand, Prof and Haioun, Corinne, Prof and Molina, Thierry Jo, Prof and Fermé, Christophe, MD and Casasnovas, Olivier, MD and Thiéblemont, Catherine, Prof and Bosly, André, Prof and Laurent, Guy, Prof and Morschhauser, Franck, MD and Ghesquières, Hervé, MD and Jardin, Fabrice, Prof and Bologna, Serge, MD and Fruchart, Christophe, MD and Corront, Bernadette, MD and Gabarre, Jean, MD and Bonnet, Christophe, MD and Janvier, Maud, MD and Canioni, Danielle, Prof and Jais, Jean-Philippe, MD and Salles, Gilles, Prof and Tilly, Hervé, Dr, Prof and Grp Etud Lymphomes Adulte and Groupe d'Etude des Lymphomes de l'Adulte
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
by Ribrag, Vincent, Dr and Koscielny, Serge, PhD and Bosq, Jacques, MD and Leguay, Thibaut and Casasnovas, Olivier, MD and Fornecker, Luc-Mathieu and Recher, Christian and Ghesquieres, Hervé, MD and Morschhauser, Franck, Prof and Girault, Stéphane, MD and Gouill, Steven Le, Prof and Ojeda-Uribe, Mario, MD and Mariette, Clara, MD and Cornillon, Jerome, MD and Cartron, Guillaume, Prof and Verge, Veronique, MD and Chassagne-Clément, Catherine, MD and Dombret, Hervé, Prof and Coiffier, Bertrand, Prof and Lamy, Thierry, Prof and Tilly, Hervé, Prof and Salles, Gilles, Prof
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
by Ravandi, Farhad, Prof and Ritchie, Ellen K, MD and Sayar, Hamid, MD and Lancet, Jeffrey E, MD and Craig, Michael D, MD and Vey, Norbert, Prof and Strickland, Stephen A, MD and Schiller, Gary J, Prof and Jabbour, Elias, MD and Erba, Harry P, Prof and Pigneux, Arnaud, Prof and Horst, Heinz-August, Prof and Recher, Christian, Prof and Klimek, Virginia M, MD and Cortes, Jorge, Prof and Roboz, Gail J, MD and Odenike, Olatoyosi, MD and Thomas, Xavier, MD and Havelange, Violaine, MD and Maertens, Johan, Prof and Derigs, Hans-Günter, Prof and Heuser, Michael, MD and Damon, Lloyd, Prof and Powell, Bayard L, Prof and Gaidano, Gianluca, Prof and Carella, Angelo-Michele, MD and Wei, Andrew, MBBS and Hogge, Donna, Prof and Craig, Adam R, MD and Fox, Judith A, PhD and Ward, Renee, MD and Smith, Jennifer A, PhD and Acton, Gary, MD and Mehta, Cyrus, Prof and Stuart, Robert K, MD and Kantarjian, Hagop M, Prof
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1025 - 1036
Summary Background Safe and effective treatments are urgently needed for patients with relapsed or refractory acute myeloid leukaemia. We investigated the... 
Hematology, Oncology and Palliative Medicine | TRIALS | CELLS | MITOXANTRONE | ONCOLOGY | VORELOXIN | RISK | OUTCOMES | DOSE CYTOSINE-ARABINOSIDE | SAMPLE-SIZE | COMBINATION | CHEMOTHERAPY | Double-Blind Method | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols | Neoplasm Recurrence, Local - drug therapy | Male | Thiazoles - administration & dosage | Treatment Outcome | Remission Induction | Cytarabine - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Naphthyridines - administration & dosage | Relapse | Care and treatment | Diseases | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Extracellular ATP and CD39 Regulates Mitochondrial Function and Cytarabine Resistance through Intrinsic PKA-ATF-PGC1a Pathway in Acute Myeloid Leukemia
by Sarry, Jean-Emmanuel and Recher, Christian and Aroua, Nesrine
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2737 - 2737
Abstract Relapses in acute myeloid leukemia (AML) are caused by chemoresistant leukemic populations and new therapeutic approaches that specifically target... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Adrenomedullin Receptor Calcrl Drives Drug Resistance of Leukemic Stem Cells in Acute Myeloid Leukemia
by Sarry, Jean-Emmanuel and Recher, Christian and Larrue, Clément
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1449 - 1449
Abstract After intensive chemotherapy, the emergence of cells with drug resistant and/or stem cell features might explain frequent relapses and the poor... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
by Thomas Prébet and Steven D. Gore and Benjamin Esterni and Claude Gardin and Raphael Itzykson and Sylvain Thepot and François Dreyfus and Odile Beyne Rauzy and Christian Recher and Lionel Adès and Bruno Quesnel and C.L. Beach and Pierre Fenaux and Norbert Vey
Journal of Clinical Oncology, ISSN 0732-183X, 08/2011, Volume 29, Issue 24, pp. 3322 - 3327
Purpose Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic... 
DECITABINE | TRIALS | THERAPY | RESPONSE CRITERIA | DNA METHYLATION | NEOPLASMS | ONCOLOGY | ACUTE MYELOID-LEUKEMIA | CANCER | PROGRESSION | INTERNATIONAL WORKING GROUP | Azacitidine - adverse effects | Prognosis | Follow-Up Studies | Humans | Middle Aged | Male | Antimetabolites, Antineoplastic - therapeutic use | Treatment Failure | Antimetabolites, Antineoplastic - adverse effects | Myelodysplastic Syndromes - mortality | Female | Aged | Myelodysplastic Syndromes - drug therapy | Azacitidine - therapeutic use | Cohort Studies | ORIGINAL REPORTS | Hema5 | Hema6
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy
by Moschoi, Ruxanda and Imbert, Véronique and Nebout, Marielle and Chiche, Johanna and Mary, Didier and Prebet, Thomas and Saland, Estelle and Castellano, Rémy and Pouyet, Laurent and Collette, Yves and Vey, Norbert and Chabannon, Christian and Recher, Christian and Sarry, Jean-Emmanuel and Alcor, Damien and Peyron, Jean-François and Griessinger, Emmanuel
Blood, ISSN 0006-4971, 07/2016, Volume 128, Issue 2, pp. 253 - 264
Here we demonstrate that in a niche-like coculture system, cells from both primary and cultured acute myeloid leukemia (AML) sources take up functional... 
INITIATING CELLS | CANCER-CELLS | STEM-CELLS | SERINE-PROTEASE | CHEMORESISTANCE | HEMATOLOGY | EXPRESSION | Neoplasm Transplantation | Leukemia, Myeloid, Acute - pathology | Stromal Cells - pathology | Coculture Techniques | Humans | Leukemia, Myeloid, Acute - metabolism | Stromal Cells - metabolism | Bone Marrow Cells - pathology | Mitochondria - metabolism | Mitochondria - pathology | Animals | Heterografts | Mice, Nude | U937 Cells | HL-60 Cells | Mice | Bone Marrow Cells - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
by Dombret, Hervé and Seymour, John F and Butrym, Aleksandra and Wierzbowska, Agnieszka and Selleslag, Dominik and Jang, Jun Ho and Kumar, Rajat and Cavenagh, James and Schuh, Andre C and Candoni, Anna and Récher, Christian and Sandhu, Irwindeep and Del Castillo, Teresa Bernal and Al-Ali, Haifa Kathrin and Martinelli, Giovanni and Falantes, Jose and Noppeney, Richard and Stone, Richard M and Minden, Mark D and McIntyre, Heidi and Songer, Steve and Lucy, Lela M and Beach, C.L and Döhner, Hartmut
Blood, ISSN 0006-4971, 07/2015, Volume 126, Issue 3, pp. 291 - 299
This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and safety vs conventional care regimens (CCRs) in 488 patients age >=... 
SEQUENTIAL AZACITIDINE | SURVIVAL | SUPPORTIVE CARE | INTENSIVE CHEMOTHERAPY | AGMT-STUDY GROUP | LOW-DOSE CYTARABINE | OPEN-LABEL | ACUTE MYELOID-LEUKEMIA | RISK MYELODYSPLASTIC SYNDROMES | HEMATOLOGY | ELDERLY-PATIENTS | Blast Crisis - drug therapy | Blast Crisis - pathology | Prognosis | Prospective Studies | Follow-Up Studies | Leukemia, Myeloid, Acute - pathology | Humans | Male | Survival Rate | Leukemia, Myeloid, Acute - mortality | Antimetabolites, Antineoplastic - therapeutic use | International Agencies | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Neoplasm Staging | Azacitidine - therapeutic use | Plenary Paper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs
by Bossis, Guillaume and Sarry, Jean-Emmanuel and Kifagi, Chamseddine and Ristic, Marko and Saland, Estelle and Vergez, François and Salem, Tamara and Boutzen, Héléna and Baik, Hayeon and Brockly, Frédérique and Pelegrin, Mireia and Kaoma, Tony and Vallar, Laurent and Récher, Christian and Manenti, Stéphane and Piechaczyk, Marc
Cell Reports, ISSN 2211-1247, 06/2014, Volume 7, Issue 6, pp. 1815 - 1823
Chemotherapeutic drugs used in the treatment of acute myeloid leukemias (AMLs) are thought to induce cancer cell death through the generation of DNA... 
OXIDATION | APOPTOSIS | ACTIVATION | MODIFIER | SUMO | INHIBITION | UBIQUITIN | DAUNORUBICIN | CANCER | SUMOYLATION | CELL BIOLOGY | Cytarabine - pharmacology | Reactive Oxygen Species - metabolism | Humans | Leukemia, Myeloid, Acute - metabolism | Daunorubicin - pharmacology | Etoposide - pharmacology | Male | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Microarray Analysis | U937 Cells | HL-60 Cells | Leukemia, Myeloid, Acute - drug therapy | Female | Antineoplastic Agents - pharmacology | Mice | SUMO-1 Protein - metabolism | Apoptosis | Disease Models, Animal
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial
by Stefan Faderl and Meir Wetzler and David Rizzieri and Gary Schiller and Madan Jagasia and Robert Stuart and Siddhartha Ganguly and David Avigan and Michael Craig and Robert Collins and Michael Maris and Tibor Kovacsovics and Stuart Goldberg and Karen Seiter and Parameswaran Hari and Jochen Greiner and Norbert Vey and Christian Recher and Farhad Ravandi and Eunice S. Wang and Michael Vasconcelles and Dirk Huebner and Hagop M. Kantarjian
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 20, pp. 2492 - 2499
Purpose To compare the receipt of clofarabine plus cytarabine (Clo + Ara-C arm) with cytarabine (Ara-C arm) in patients > 55 years old with refractory or... 
PHASE-III TRIAL | ETOPOSIDE | MULTICENTER | MITOXANTRONE | ONCOLOGY | RISK MYELODYSPLASTIC SYNDROME | ACUTE MYELOID-LEUKEMIA | STEM-CELL TRANSPLANTATION | ARA-C | COMBINATION | CHEMOTHERAPY | Recurrence | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Male | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Arabinonucleosides - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Placebos | Female | Aged | Adenine Nucleotides - administration & dosage | Index Medicus | ORIGINAL REPORTS | Hema5
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
by Jaccard, Arnaud and Moreau, Philippe and Leblond, Veronique and Leleu, Xavier and Benboubker, Lotfi and Hermine, Olivier and Recher, Christian and Asli, Bouchra and Lioure, Bruno and Royer, Bruno and Jardin, Fabrice and Bridoux, Frank and Grosbois, Bernard and Jaubert, Jérome and Piette, Jean-Charles and Ronco, Pierre and Quet, Fabrice and Cogne, Michel and Fermand, Jean-Paul and Intergroupe Francophone and Myelome Autogreffe MAG and Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup
The New England Journal of Medicine, ISSN 0028-4793, 09/2007, Volume 357, Issue 11, pp. 1083 - 1093
Myeloablative doses of melphalan with rescue by autologous hematopoietic stem cells are currently used in the treatment of immunoglobulin-light-chain (AL)... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | PREDNISONE | COLCHICINE | THERAPY | PRIMARY SYSTEMIC AMYLOIDOSIS | IMMUNOGLOBULIN LIGHT-CHAINS | STEM-CELL TRANSPLANTATION | BLOOD | Amyloidosis - therapy | Dexamethasone - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Amyloidosis - mortality | Hematopoietic Stem Cell Transplantation | Male | Amyloidosis - drug therapy | Combined Modality Therapy | Disease Progression | Immunoglobulin Light Chains | Melphalan - administration & dosage | Myeloablative Agonists - administration & dosage | Female | Aged | Drug Therapy, Combination | Dosage and administration | Amyloidosis | Dexamethasone | Comparative analysis | Drug therapy | Melphalan | Bone marrow | Mortality | Stem cells | Life Sciences | Immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients
by Berger, E and Delpierre, C and Despas, F and Bertoli, S and Berard, E and Bombarde, O and Bories, P and Sarry, A and Laurent, G and Recher, C and Lamy, S
BMC CANCER, ISSN 1471-2407, 09/2019, Volume 19, Issue 1, pp. 883 - 12
Background Evidences support social inequalities in cancer survival. Studies on hematological malignancies, and more specifically Acute Myeloid Leukemia (AML),... 
CANCER SURVIVAL | DIAGNOSIS | Observational study | INTENSIVE CHEMOTHERAPY | STAGE | SOCIOECONOMIC INEQUALITIES | TIME | Elderly patients | CARE | French European deprivation index | IMPACT | Cancer management and survival | DISPARITIES | ONCOLOGY | Acute myeloid leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Catabolic Flexibility Enhances Drug Resistance but Induces Selective Vulnerability to New Mitochondrial-Targeted Therapeutic Combinations in IDH Mutant Leukemia
by Sarry, Jean-Emmanuel and Recher, Christian and Stuani, Lucille and Portais, Jean-Charles
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5238 - 5238
Abstract Isocitrate dehydrogenases IDH1/2 mutations and its oncometabolite 2-HG have been of major clinical interest as they have been causally linked to the... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights